Tryp Therapeutics appoints Greg McKee as Chief Executive Officer

SAN DIEGO: Tryp Therapeutics Inc. has appointed Greg McKee as its Chief Executive Officer, a news release said.

Mr. McKee will also continue in his responsibilities as Chairman of the Board of Directors of the Company. Mr. McKee has extensive experience leading publicly traded pharmaceutical companies and brings a vast network of relationships in the life science industry to accelerate Tryp’s drug development activities.

Mr. McKee began his life science career at Genzyme where he was responsible for commercializing leading compounds for rare diseases throughout Asia. He then served as Chairman and CEO of Nventa Biopharmaceuticals Corporation and Akela Pharma Inc., both publicly traded biopharmaceutical companies.

Most recently, Mr. McKee spent significant time supporting early stage life science and digital health companies as CEO of CONNECT, an early stage incubator, and as Managing Director at Torrent Ventures. He was previously appointed as Chairman of the Board of Directors of Tryp in February 2021.

William Garner, M.D., Executive Director of the Company, commented, “Greg has provided exceptional vision and leadership to Tryp since his appointment as Chairman of the Board, and he is ideally suited to lead the Company’s next phase of growth. We are fortunate to have him serve the company in this expanded capacity as Chief Executive Officer.”

The Company’s former CEO, Jim Kuo, will continue to serve as a director on the Company’s board.

“We express our sincere gratitude to Jim Kuo for his service to the Company as a co-founder and CEO,” said Mr. McKee.

“I am excited to build on the foundation that he and our team have established at Trypas we advance our groundbreaking clinical programs in chronic pain, eating disorders, oncology, and other indications. It is an exceptional time to be advancing the science and available therapies using our proprietary psilocybin and other small molecule formulations.”

In connection with his appointment, Mr. McKee has been granted an aggregate of 2.3 million additional stock options. The Options have an exercise price of $0.68 per share, are exercisable until March 31, 2031 (subject to vesting restrictions) and will be governed in accordance with the terms of the Company’s stock option plan.

www.tryptherapeutics.com

Leave a Reply

Your email address will not be published. Required fields are marked *